Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trialJerry S. Wolinsky, Stephen L. Hauser, James Overell et al.|The Lancet Neurology|2020Cited by 150